Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akumin Inc. stock logo
AKU
Akumin
$0.18
$0.12
$1.90
$26.32M-0.721.38 million shs8.54 million shs
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.33
-14.8%
$0.32
$0.25
$1.19
$17.03M1.19171,919 shs4.12 million shs
MDxHealth SA stock logo
MDXH
MDxHealth
$2.20
+0.9%
$2.09
$1.35
$3.50
$103.09M1.3190,180 shs39,259 shs
OpGen, Inc. stock logo
OPGN
OpGen
$4.60
+13.6%
$4.77
$0.53
$5.25
$40.78M-1.668,973 shs1,396 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akumin Inc. stock logo
AKU
Akumin
0.00%0.00%0.00%0.00%0.00%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00%0.00%0.00%+0.62%-71.74%
MDxHealth SA stock logo
MDXH
MDxHealth
+0.92%0.00%+10.55%+37.50%-24.14%
OpGen, Inc. stock logo
OPGN
OpGen
+13.58%0.00%-6.12%+10.31%+49.30%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Akumin Inc. stock logo
AKU
Akumin
N/AN/AN/AN/AN/AN/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/AN/AN/AN/AN/AN/AN/AN/A
MDxHealth SA stock logo
MDXH
MDxHealth
2.0937 of 5 stars
3.53.00.00.02.20.00.6
OpGen, Inc. stock logo
OPGN
OpGen
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akumin Inc. stock logo
AKU
Akumin
0.00
N/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00
N/AN/AN/A
MDxHealth SA stock logo
MDXH
MDxHealth
3.00
Buy$6.50195.45% Upside
OpGen, Inc. stock logo
OPGN
OpGen
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akumin Inc. stock logo
AKU
Akumin
$749.63M0.00N/AN/A$1.24 per share0.00
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$29.09M0.59N/AN/A$1.09 per share0.30
MDxHealth SA stock logo
MDXH
MDxHealth
$90.05M1.16N/AN/A$0.31 per share7.10
OpGen, Inc. stock logo
OPGN
OpGen
$2.67M17.33N/AN/A($11.55) per share-0.40
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akumin Inc. stock logo
AKU
Akumin
-$156.76M-$2.52N/AN/AN/A-30.56%-167.86%-7.81%N/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
-$26.08MN/A0.00N/A-75.34%-7.96%-5.49%N/A
MDxHealth SA stock logo
MDXH
MDxHealth
-$38.07M-$1.15N/AN/AN/A-41.02%-492.11%-23.00%8/20/2025 (Estimated)
OpGen, Inc. stock logo
OPGN
OpGen
-$32.67MN/A0.00N/A-1,140.36%N/A-287.58%N/A

Latest AKU, OPGN, ENZ, and MDXH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
MDxHealth SA stock logo
MDXH
MDxHealth
-$0.13-$0.19-$0.06-$0.19$22.62 million$24.29 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Akumin Inc. stock logo
AKU
Akumin
N/AN/AN/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.40123.08%N/AN/AN/A
MDxHealth SA stock logo
MDXH
MDxHealth
N/AN/AN/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akumin Inc. stock logo
AKU
Akumin
17.02
0.99
0.99
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/A
2.55
2.28
MDxHealth SA stock logo
MDXH
MDxHealth
13.81
2.00
1.92
OpGen, Inc. stock logo
OPGN
OpGen
N/A
5.45
5.45

Institutional Ownership

CompanyInstitutional Ownership
Akumin Inc. stock logo
AKU
Akumin
36.10%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
36.90%
MDxHealth SA stock logo
MDXH
MDxHealth
N/A
OpGen, Inc. stock logo
OPGN
OpGen
2.68%

Insider Ownership

CompanyInsider Ownership
Akumin Inc. stock logo
AKU
Akumin
20.51%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
11.40%
MDxHealth SA stock logo
MDXH
MDxHealth
1.70%
OpGen, Inc. stock logo
OPGN
OpGen
43.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Akumin Inc. stock logo
AKU
Akumin
3,63191.17 million72.47 millionNot Optionable
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
52052.40 million46.29 millionOptionable
MDxHealth SA stock logo
MDXH
MDxHealth
30047.29 million46.48 millionNot Optionable
OpGen, Inc. stock logo
OPGN
OpGen
10010.07 million4.70 millionNot Optionable

Recent News About These Companies

OpGen Forms Joint Venture with European Bank
OpGen Appoints New COO and Company Secretary
OPGN Stock Earnings: OpGen Reported Results for Q2 2024
OPGN Stock Earnings: OpGen Meets Revenue for Q4 2023
OpGen, Inc.: OpGen Announced 1-for-10 Reverse Stock Split
OpGen Announced 1-for-10 Reverse Stock Split

New MarketBeat Followers Over Time

Media Sentiment Over Time

Akumin stock logo

Akumin NASDAQ:AKU

Akumin Inc. provides outpatient diagnostic imaging services in the United States. It operates in two segments, Radiology and Oncology. The company offers various medical imaging services, including magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other diagnostic and interventional radiology procedures through owned and/or operated imaging locations. It provides outpatient radiology, and oncology services and solutions to hospitals and health systems across 48 states. Akumin Inc. was founded in 2015 and is headquartered in Plantation, Florida.

Enzo Biochem stock logo

Enzo Biochem NYSE:ENZ

Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents. The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.

MDxHealth stock logo

MDxHealth NASDAQ:MDXH

$2.20 +0.02 (+0.92%)
As of 07/16/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

OpGen stock logo

OpGen NASDAQ:OPGN

$4.60 +0.55 (+13.58%)
As of 07/16/2025 09:57 AM Eastern

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.